TAVI with Evolut R device in low risk patients

Live Case Broadcasted by TBR Productions from Toulouse, France to Rio de Janeiro, Brazil, where took place the SOLACI-SBHCI 2016 Congress.

Panelists: Rafael Cavalcante e Silva – BRAZIL, Patrick W. Serruys – UK, Samir Kapadia – USA, Jorge Atilio Belardi – ARGENTINA.

More articles by this author

Bringing More MIL / MINT to Light Through CLIMB Grants – Check out our educational event again

You can now relive our virtual event on "Bringing More MIL / MINT to Light Through CLIMB Grants", held last May 2 on our...

The Visible Heart Lab – Rewatch now our event on coronary bifurcations

You can now relive our virtual event on “The Visible Heart Lab” on Forks, held in conjunction with Medtronic. The event was held on April...

Challenging Borders and Advancing Together: Women at the Forefront of Hemodynamics – Watch again our webinar

You can now relive our virtual event on "Defying borders and moving forward together: women at the forefront in hemodynamics" on our YouTube channel. The...

Watch Again the Turning Point on the Treatment of HTN

You can now relive our virtual event on The turning point in the treatment of HTN on our YouTube channel. The event took place last...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....